InsidersTradesSigma
Total declarations
Company
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
1
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the detailed record of transactions filed by Spaventa Andrew, Chief Executive Officer. Director active across 1 company, notably Singular Genomics Systems, Inc.. In total, 16 reports have been logged. Breakdown: 1 buy · 0 sell. Total volume traded: €16k. History available since 16 November 2023. The latest transaction was filed on 16 November 2023 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Spaventa Andrew
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations16 total
325 sharesCommon StockSEC:0000950170-25-027112:0
1,907 sharesCommon StockSEC:0000950170-25-021402:0
486 sharesCommon StockSEC:0000950170-24-137425:0
1,907 sharesCommon StockSEC:0000950170-24-126428:0
487 sharesCommon StockSEC:0000950170-24-107502:0
1,906 sharesCommon StockSEC:0000950170-24-097190:0
14,584 sharesCommon StockSEC:0000950170-24-075034:0
57,188 sharesCommon StockSEC:0000950170-24-058955:0
14,583 sharesCommon StockSEC:0001209191-24-004948:0
14,583 sharesCommon StockSEC:0001209191-23-059005:0
43,468 shares@ US$0.4108100.0% of flowCommon StockSEC:0001209191-23-056071:0
Canonical exit: 14 Feb 2024 (T+90)
14,584 sharesCommon StockSEC:0001209191-23-049652:0
14,583 sharesCommon StockSEC:0001209191-23-038481:0
173,144 sharesCommon StockSEC:0001209191-22-021034:0
715,884 sharesCommon StockSEC:0001209191-21-068185:0
715,884 sharesCommon StockSEC:0001209191-21-037022:0
16 of 16 declarations
About Spaventa Andrew
Spaventa Andrew is Directeur Général at Singular Genomics Systems, Inc. (XNAS), where his listed role is Chief Executive Officer. He has filed 16 disclosures in total, and across the 16 sampled filings the reported buy volume is 16451 euros, the sell volume is 0 euros, with transactions mainly related to an option exercise, from 2021-06-01 to 2025-02-25.
